• Home
  •  / ThermoGenesis

ThermoGenesis

OverviewSuggest Edit

ThermoGenesis Holdings (formerly known as Cesca Therapeutics) is a regenerative medicine company that develops, commercializes and markets a range of automated technologies for cell-based therapeutics. Its device division provides a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. ThermoGenesis’s clinical development division is leveraging its proprietary AutoXpress technology platform to develop stem cell-based therapies in the immuno-oncology, vascular, cardiology and orthopedic markets.

TypePublic
Founded1986
HQRancho Cordova, USMap
Websitethermogenesis.com
Employee Ratings2.3More
View Jobs (1)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2018)53(-38%)
Job Openings1
Revenue (FY, 2019)$13 M(+35%)
Share Price (Aug 2020)$5.7 (-11%)
Cybersecurity ratingAMore

Key People/Management at ThermoGenesis

Chris Xu

Chris Xu

Chairman, Chief Executive Officer
Philip Coelho

Philip Coelho

Chief Technology Officer
Mark Westgate

Mark Westgate

Director
Debra Donaghy

Debra Donaghy

Director
Russell Medford

Russell Medford

Director
Jeff Cauble

Jeff Cauble

Chief Financial Officer
Show more

ThermoGenesis Office Locations

ThermoGenesis has offices in Rancho Cordova and Wuxi Shi
Rancho Cordova, US (HQ)
2711 Citrus Rd
Wuxi Shi, CN
800 Jiefang E Rd, Zhong Shan Lu, Liangxi Qu
Show all (2)

ThermoGenesis Financials and Metrics

ThermoGenesis Revenue

Embed Graph
View revenue for all periods
ThermoGenesis's revenue was reported to be $13.05 m in FY, 2019
USD

Revenue (Q1, 2020)

3.2m

Gross profit (Q1, 2020)

1.5m

Gross profit margin (Q1, 2020), %

46.6%

Net income (Q1, 2020)

(4.7m)

EBIT (Q1, 2020)

(1.2m)

Market capitalization (11-Aug-2020)

36.0m

Closing stock price (11-Aug-2020)

5.7

Cash (31-Mar-2020)

5.7m

EV

32.8m
ThermoGenesis's current market capitalization is $36 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

19.0m18.0m16.0m16.0m11.9m6.0m9.7m13.0m

Revenue growth, %

0%(26%)

Cost of goods sold

12.7m11.6m10.1m11.3m9.2m3.9m7.5m7.4m

Gross profit

6.3m6.4m5.9m4.7m2.7m2.2m2.2m5.7m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

4.9m4.8m4.9m4.1m4.8m4.9m3.6m4.5m4.0m3.7m4.6m4.0m2.8m3.3m2.8m3.8m4.0m3.3m3.1m1.9m2.0m3.1m3.0m4.3m4.1m3.2m

Cost of goods sold

2.9m3.1m3.7m2.5m2.8m3.2m2.3m2.7m2.5m2.5m3.1m2.9m2.5m2.3m2.4m2.4m2.5m1.9m9.9m1.5m1.6m2.5m1.7m2.4m2.2m1.7m

Gross profit

2.0m1.7m1.2m1.6m2.0m1.7m1.4m1.8m1.5m1.2m1.5m1.1m367.0k1.0m408.0k1.4m1.6m1.4m(6.8m)352.0k363.0k655.0k1.3m2.0m1.9m1.5m

Gross profit Margin, %

41%36%24%39%41%34%38%40%38%32%33%28%13%31%14%37%39%42%(221%)19%18%21%42%45%47%47%
show all
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

7.9m6.9m14.8m3.4m5.8m3.5m2.4m3.2m

Accounts Receivable

4.6m4.9m4.7m5.1m1.7m1.5m1.3m

Prepaid Expenses

338.0k232.0k217.0k163.0k594.0k224.0k602.0k

Inventories

6.3m4.3m5.6m4.6m4.8m4.5m3.8m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

10.8m8.7m8.5m8.8m7.5m7.5m5.3m2.3m6.6m10.7m8.4m4.8m6.6m2.9m7.2m5.6m4.9m3.8m2.5m2.9m3.1m2.2m2.2m2.4m2.8m5.7m

Accounts Receivable

4.4m5.0m4.8m3.5m5.4m4.9m4.2m5.5m5.6m4.4m4.6m5.7m3.6m3.5m4.0m3.0m3.0m3.0m258.0k1.5m2.1m2.0m3.1m4.5m2.0m

Prepaid Expenses

315.0k170.0k111.0k366.0k420.0k338.0k319.0k136.0k198.0k490.0k300.0k200.0k131.0k336.0k262.0k203.0k260.0k334.0k557.0k286.0k313.0k389.0k451.0k429.0k

Inventories

6.6m6.8m6.4m6.2m5.4m4.3m4.4m4.2m4.8m5.9m5.2m5.0m4.0m4.0m3.5m3.4m2.8m3.5m282.0k5.2m4.3m4.3m4.0m3.4m4.2m
show all
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(5.0m)(3.1m)(8.6m)(14.9m)(18.6m)(2.8m)(40.9m)(10.1m)

Depreciation and Amortization

604.0k538.0k993.0k1.4m1.2m322.0k670.0k805.0k

Inventories

120.0k795.0k(1.3m)416.0k375.0k(367.0k)61.0k610.0k

Accounts Payable

696.0k619.0k(295.0k)1.4m(2.4m)469.0k214.0k(966.0k)
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(1.2m)(2.5m)(4.2m)995.0k432.0k(689.0k)(2.3m)(3.9m)(5.8m)(3.3m)(7.7m)(12.5m)(3.4m)(4.0m)(14.9m)(22.4m)(25.8m)(27.9m)(3.4m)(30.5m)(33.6m)(2.0m)(3.5m)(5.9m)(4.7m)

Depreciation and Amortization

99.0k202.0k388.0k134.0k266.0k400.0k156.0k327.0k587.0k322.0k667.0k1.0m365.0k659.0k876.0k261.0k473.0k660.0k159.0k333.0k506.0k212.0k402.0k604.0k199.0k

Inventories

230.0k(322.0k)20.0k13.0k710.0k994.0k(162.0k)7.0k(430.0k)(332.0k)157.0k66.0k594.0k568.0k568.0k258.0k811.0k599.0k(224.0k)(358.0k)336.0k99.0k449.0k980.0k(400.0k)

Accounts Payable

29.0k(143.0k)131.0k(982.0k)(1.1m)(1.1m)112.0k(369.0k)(397.0k)(571.0k)(404.0k)1.1m300.0k(626.0k)(1.7m)(832.0k)(587.0k)(738.0k)69.0k(242.0k)(407.0k)38.0k749.0k(542.0k)1.0m
show all
USDQ1, 2012

Financial Leverage

1.2 x
Show all financial metrics

ThermoGenesis Operating Metrics

FY, 2016

Patents Issued

25
Show all operating metrics

ThermoGenesis Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

Learn more about about our premium products
SecurityScorecard logo

ThermoGenesis Online and Social Media Presence

ThermoGenesis's Trends

Embed Graph

ThermoGenesis News and Updates

March 27, 2020

ThermoGenesis Holdings Announces Closing Of $3.5 Million Registered Direct Offering Priced At-the-Market

RANCHO CORDOVA, Calif., March 27, 2020 /PRNewswire/ -- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that it closed its previously announced registered direct offering for...
October 31, 2019

Cesca Therapeutics To Change Name And Ticker Symbol To Reflect New Strategic Focus

RANCHO CORDOVA, Calif., Oct. 31, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing for regenerative medicine, today announced that the company will change its name to ThermoGenesis Holdings, Inc. ("ThermoGenesis") in order to better...
October 22, 2019

Cesca Therapeutics Forms Joint Venture with Healthbanks Biotech (USA) to Provide Immune Cell Banking and Cell Processing Services

RANCHO CORDOVA, Calif., Oct. 22, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ThermoGenesis, its wholly owned device subsidiary, today announced that the company has...
September 03, 2019

Cesca Therapeutics To Present At The H.C. Wainwright 21st Annual Global Investment Conference

RANCHO CORDOVA, Calif., Sept. 3, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced Jeff Cauble, Vice President of Finance and Principal Accounting Officer, will...
June 04, 2019

Cesca Therapeutics Announces 1-for-10 Reverse Split Of Common Stock

RANCHO CORDOVA, Calif., June 4, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced that it has amended its Sixth Amended and Restated Certificate of...
May 14, 2019

Cesca Therapeutics Announces First Quarter 2019 Financial Results And Provides Corporate Update

RANCHO CORDOVA, Calif., May 14, 2019 /PRNewswire/ -- Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced financial and operating results for the first quarter ended March 31, 2019 and ...
Show more

ThermoGenesis Blogs

November 14, 2019

ThermoGenesis Holdings to Postpone Third Quarter 2019 Earnings Release and Conference Call Until Tuesday November 19, 2019

RANCHO CORDOVA, Calif., Nov. 14, 2019 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO) formerly known as Cesca Therapeutics Inc., a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced it will delay its third quarter ended September 30, 2019 …
November 12, 2019

ThermoGenesis Holdings to Delay Third Quarter 2019 Earnings Release and Conference Call Until Thursday November 14, 2019

RANCHO CORDOVA, Calif., Nov. 12, 2019 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), formerly known as Cesca Therapeutics Inc., a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced  it will delay its third quarter ended September 30, 201…
November 06, 2019

ThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2019 and Provide a Corporate Strategic Update

Conference Call to be Held on November 12, 2019 RANCHO CORDOVA, Calif., Nov. 6, 2019 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing for regenerative medicine, today announced that the Company will release its financial results for the third quarter ended …
October 31, 2019

Cesca Therapeutics to Change Name and Ticker Symbol to Reflect New Strategic Focus

ThermoGenesis to Focus on Developing Automated Cell Processing Tools and Services for the Cell and Gene Therapy Field RANCHO CORDOVA, Calif., Oct. 31, 2019 — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing for regenerative medicine, today announced that the compa…
October 29, 2019

Dawson James 5th Annual Small Cap Growth Stock Conference

Disclosure and Forward Looking Statement — This presentation includes statements of future expectations and other forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current …
October 24, 2019

Cesca Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

Cesca Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference Content Import Thu, 10/24/2019 - 08:30 Cesca Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference October 24, 2019 This rel…
Show more

 ThermoGenesis Frequently Asked Questions

  • When was ThermoGenesis founded?

    ThermoGenesis was founded in 1986.

  • Who are ThermoGenesis key executives?

    ThermoGenesis's key executives are Chris Xu, Philip Coelho and Mark Westgate.

  • How many employees does ThermoGenesis have?

    ThermoGenesis has 53 employees.

  • What is ThermoGenesis revenue?

    Latest ThermoGenesis annual revenue is $13 m.

  • What is ThermoGenesis revenue per employee?

    Latest ThermoGenesis revenue per employee is $246.2 k.

  • Who are ThermoGenesis competitors?

    Competitors of ThermoGenesis include Neuronasal, BioFactura and Respivant Sciences.

  • Where is ThermoGenesis headquarters?

    ThermoGenesis headquarters is located at 2711 Citrus Rd, Rancho Cordova.

  • Where are ThermoGenesis offices?

    ThermoGenesis has offices in Rancho Cordova and Wuxi Shi.

  • How many offices does ThermoGenesis have?

    ThermoGenesis has 2 offices.